Eduardo Garcia-Ferrer
Psychiatry · Saint Louis, MONPI 1619917101
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,600 of the $17,939 with a category attached, or 81.4%. 6 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 55.0% of the total. Reporting peaked in 2019 at $16,715 and has fallen 99.3% since, to $124 in 2024. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 40 payments — averaging $448.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$10K
- Sunovion Pharmaceuticals Inc.$8K
- Teva Pharmaceuticals USA, Inc.$219
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$126
- Genmab U.S., Inc.$31
- E.r. Squibb & Sons, L.L.C.$19
What the payments were for
- Speaking & faculty fees$14,60081%
- Travel & lodging$2,18612%
- Food & beverage$1,1536%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $9,866 |
| Sunovion Pharmaceuticals Inc. | 21 | $7,678 |
| Teva Pharmaceuticals USA, Inc. | 2 | $219 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $126 |
| Genmab U.S., Inc. | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$9,616
- LATUDA$7,524
- Austedo XR$219
- CAPLYTA$126
How this compares
$17,939 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 44 | $4,114 |
| Alprazolam | 148 | $2,646 |
| Quetiapine Fumarate | 69 | $1,066 |
| Bupropion XlBupropion Hcl | 28 | $582 |
| Trazodone Hcl | 106 | $549 |
| Buspirone Hcl | 57 | $531 |
| Duloxetine Hcl | 74 | $511 |
| Mirtazapine | 78 | $477 |
| Olanzapine | 28 | $308 |
| Doxepin Hcl | 14 | $297 |
| Paroxetine Hcl | 20 | $218 |
| Lorazepam | 33 | $177 |
| Lamotrigine | 35 | $148 |
| Escitalopram Oxalate | 31 | $131 |
| Clonazepam | 14 | $95 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Saint Louis
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- George GrossbergSaint Louis$501K
- Christopher LoyndSaint Louis$265K
- Devnandini RastogiSaint Louis$261K
- Michael StotlerSaint Louis$250K
- James ChoSaint Louis$118K
- Steven HarveySaint Louis$90K
- Kevin BlackSaint Louis$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.